Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Mercator Medsystems Inc. is managing 4 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 4 distinct examiners, yet they are all contained within 1 distinct art unit. This suggests that while the company has multiple active matters, they are all being evaluated within the same technical group at the USPTO. The concentration in this specific art unit provides a unified technical context for the assigned personnel to review the company's medical device innovations.
RAHMANI, NILOOFAR is the busiest examiner for the portfolio, currently handling 1 pending office action. Since the workload is distributed among 4 distinct examiners, the assigned personnel can focus on individual matters. The company can leverage the consistency of the 1 distinct art unit to ensure that its arguments remain uniform across all 4 pending office actions. This approach helps maintain a cohesive strategy for the company's mechanical engineering filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| GRAY, PHILLIP A | 1 | 74.4% | +10.5% |
| BOSWORTH, KAMI A | 1 | 69.1% | +28.7% |
| KOO, BENJAMIN K | 1 | 57.1% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 91d overdue |
| 18667884 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | RAHMANI, NILOOFAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 91d overdue |
| 18626751 | TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE | GRAY, PHILLIP A | — |
| 17491036 | PERIVASCULAR ANTI-INFLAMMATORY THERAPY FOR VENOUS THROMBOSIS | KOO, BENJAMIN K | — |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667884 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | RAHMANI, NILOOFAR | — | §101§102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18626751 | TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE | GRAY, PHILLIP A | — | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 3783 | §103§112 | Final Rejection | 91d overdue | Pending | Apr 07, 2023 |
| 17491036 | PERIVASCULAR ANTI-INFLAMMATORY THERAPY FOR VENOUS THROMBOSIS | KOO, BENJAMIN K | 3783 | §103 | Non-Final OA | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial